Omada Health Inc

OMDA

Market cap $711M

Omda AS (CSAMF) Q4 2025 Earnings Call Transcript

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol,1 yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level (

SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday, March 5, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.

Omada Health, Inc. (OMDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis , findings underscore the program's role in helping employers manage the complexity of today's weight loss medication market while delivering measurable, long-term value.1 The new analysis found that members who stayed in the program and persisted on their medication for 12 months had an average weight loss of 18.4% at one year,1 compared to 11.9% weight loss seen in real world evidence.2 Among those who persisted, Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide,1 compared to published real world evidence.2 Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss1 – nearly twice the amount observed in the real world analysis.2 “The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits.

SAN FRANCISCO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, including a presentation on Wednesday, Jan. 14, at 9 a.m.

Omada Health remains a 'Buy' as Q3 results validated strong growth, with revenue up 50% y/y to $68 million and membership reaching 831,000. OMDA's new GLP-1 prescribing capability deepens client integration, enhances ROI, and strengthens competitive positioning in a complex medication landscape. Multi-condition adoption accelerated, with ~75% of new customers using multiple programs, driving operating leverage and reducing client churn risk for OMDA.

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events . A replay will also be available at the same link following the event.

Pune, India, Nov. 18, 2025 (GLOBE NEWSWIRE) -- QKS Group announced that it has named Omada a Technology Leader and Emerging Innovator in the analysis of the global SPARK MatrixTM: Identity Governance and Administration (IGA), Q4 2025. The QKS Group SPARK Matrix™ includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides competitive analysis and ranking of the leading technology vendors in the form of its SPARK MatrixTM. The study offers strategic information for users to evaluate different provider capabilities, competitive differentiation, and market position.